Thymosin Beta-4 Research Guide — What Studies Show (2026)

Healing & RecoveryPeptidesResearch

⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.

Healing & Recovery Research Strength: High

Overview

Thymosin Beta-4 is the full 43-amino-acid parent peptide of TB-500, studied for tissue repair, cardiac regeneration, and corneal healing.

What is Thymosin Beta-4?

Thymosin Beta-4 (Tβ4) is the full 43-amino-acid parent peptide that TB-500 is derived from. Most research peptide vendors sell the truncated TB-500 fragment because it's cheaper to synthesize, but the full-length Tβ4 has been the actual subject of most published clinical research.

Tβ4 is one of the most abundant intracellular proteins in human cells. Its primary biochemical role is sequestering G-actin monomers, regulating how cells build their cytoskeleton and migrate. Beyond that core function, Tβ4 has been shown to promote angiogenesis, reduce inflammation, accelerate wound healing, and stimulate stem cell mobilization.

The most notable clinical research involves cardiac regeneration. RegeneRx has run multiple Phase 2 trials examining Tβ4 in venous stasis ulcers, dry eye disease, and corneal wound healing. The corneal healing program produced some of the cleanest efficacy data — Tβ4 eye drops accelerated wound closure in neurotrophic keratitis trials.

The distinction between TB-500 and Tβ4 matters more than most research peptide vendors acknowledge. The TB-500 fragment (typically residues 17-23) captures only a small portion of Tβ4's bioactivity. Researchers comparing published Tβ4 trial results to TB-500 protocols should be aware they are not studying the same molecule.

Top Research Uses

Mechanism of Action

Sequesters G-actin to regulate cytoskeletal dynamics, promotes cell migration, angiogenesis, and reduces inflammation

Research Parameters

Half-Life ~2-3 days due to size and stability
Typical Research Dose Research literature varies; some clinical studies used 42-1260 mg over 14 days
Administration Route Subcutaneous, intravenous (in trials)
Reported Side Effects Generally well-tolerated; injection site reactions; long-term safety profile still under study

Dosing ranges cited from published research literature. These are not recommendations for human use. Thymosin Beta-4 is a research compound — not for human consumption.

Research Strength: High

Thymosin Beta-4 has a substantial body of preclinical research supporting its studied applications. Multiple independent studies have examined its mechanisms and effects in animal models.

Vendor & Sourcing Notes

Full-length Tβ4 is more expensive than the TB-500 fragment; research-grade availability is limited

Always request third-party HPLC purity reports and mass spectrometry verification when sourcing research peptides. Quality varies significantly between suppliers.

Research Use Only — Compliance Notice

The information on this page is intended for educational and informational purposes only. Thymosin Beta-4 (Thymosin Beta-4 (Tβ4)) is a research compound sold for laboratory research purposes only. It has not been approved by the FDA for human use. Nothing on this page constitutes medical advice or is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare professional before considering any peptide-related protocols.

AXI

AXI

Personal finance and AI tools writer helping people build wealth smarter. Not a licensed financial advisor.

← Back to all posts